Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

muscular dystrophy

9 posts
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-07-04
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-13
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
NNovartis
Novartis dystrophy data tee up regulatory talks on Avidity drug
Read More

Novartis dystrophy data tee up regulatory talks on Avidity drug

  • 2026-06-12
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout,…
NNovartis
Novartis Reports Positive Data for Neuromuscular Disorder Drug
Read More

Novartis Reports Positive Data for Neuromuscular Disorder Drug

  • 2026-06-11
Novartis NVS announced positive data from the biomarker cohort of the FORTITUDE phase I/II study. The FORTITUDE phase…
NNovartis
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
Read More

Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease

  • 2026-06-11
A Novartis RNA therapy reduced blood levels of a protein that’s a biological indicator of a particular form…
NNovartis
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Read More

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

  • 2026-06-11
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
NNovartis
Novartis $12bn bet on Avidity well placed after mid-stage FSHD win
Read More

Novartis $12bn bet on Avidity well placed after mid-stage FSHD win

  • 2026-06-11
Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets,…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-11
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
RRoche
Roche stops work on experimental SMA drug
Read More

Roche stops work on experimental SMA drug

  • 2026-03-20
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Switzerland
www.europesays.com